PSNP1
MCID: SPR120
MIFTS: 71

Supranuclear Palsy, Progressive, 1 (PSNP1)

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Supranuclear Palsy, Progressive, 1

MalaCards integrated aliases for Supranuclear Palsy, Progressive, 1:

Name: Supranuclear Palsy, Progressive, 1 58
Progressive Supranuclear Palsy 12 77 54 26 55 60 38 44 15 74
Steele-Richardson-Olszewski Syndrome 58 12 54 26 55 76
Supranuclear Palsy, Progressive 58 54 26 13 45
Progressive Supranuclear Ophthalmoplegia 12 26 30 6
Psp 58 54 26 76
Familial Progressive Supranuclear Palsy 54 74
Psnp1 58 76
Ophthalmoplegia, Supranuclear, Progressive 41
Progressive Supranuclear Palsy 1 76
Supranuclear Palsy Progressive 56
Richardson's Syndrome 26
Psp Syndrome 60

Characteristics:

Orphanet epidemiological data:

60
progressive supranuclear palsy
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (United States),1-9/100000 (Italy),1-5/10000 (Guadeloupe),1-9/100000 (United Kingdom),1-9/1000000 (Libyan Arab Jamahiriya),1-9/1000000 (United States),1-9/1000000 (Australia); Age of onset: Adult; Age of death: elderly;

OMIM:

58
Inheritance:
autosomal dominant

Miscellaneous:
autosomal dominant with incomplete penetrance
phenotypic overlap with frontotemporal dementia
average age at onset 66 years although earlier onset may occur
median survival 5.7 years
may show good response to levodopa
genetic heterogeneity (see psnp2 )
associated with the tau h1 haplotype


HPO:

33
supranuclear palsy, progressive, 1:
Onset and clinical course adult onset
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



Summaries for Supranuclear Palsy, Progressive, 1

MedlinePlus : 44 What is progressive supranuclear palsy (PSP)? Progressive supranuclear palsy (PSP) is a rare brain disease. It happens because of damage to nerve cells in the brain. PSP affects your movement, including control of your walking and balance. It also affects your thinking and eye movement. PSP is progressive, which means that it gets worse over time. What causes progressive supranuclear palsy (PSP)? Researchers don't know what causes most cases of PSP. In rare cases, the cause is a mutation in a certain gene. One sign of PSP is abnormal clumps of tau in nerve cells in the brain. Tau is a protein in your nervous system, including in nerve cells. Some other diseases also cause a buildup of tau in the brain, including Alzheimer's disease. Who is at risk for progressive supranuclear palsy (PSP)? PSP usually affects people over 60, but in some cases it can start earlier. It is more common in men. What are the symptoms of progressive supranuclear palsy (PSP)? Symptoms are very different in each person, but they may include A loss of balance while walking. This is often the first symptom. Speech problems Trouble swallowing A blurring of vision and problems controlling eye movement Changes in mood and behavior, including depression and apathy (a loss of interest and enthusiasm) Mild dementia How is progressive supranuclear palsy (PSP0 diagnosed? There is no specific test for PSP. It can be difficult to diagnose, because the symptoms are similar to other diseases such as Parkinson's disease and Alzheimer's disease. To make a diagnosis, your health care provider will take your medical history and do physical and neurological exams. You may have an MRI or other imaging tests. What are the treatments for progressive supranuclear palsy (PSP)? There is currently no effective treatment for PSP. Medicines may reduce some symptoms. Some non-drug treatments, such as walking aids and special glasses, may also help. People with severe swallowing problems may need gastrostomy. This is a surgery to insert a feeding tube into the stomach. PSP gets worse over time. Many people become severely disabled within three to five years after getting it. PSP isn't life-threatening on its own. It can still be be dangerous, because it increases your risk of pneumonia, choking from swallowing problems, and injuries from falling. But with good attention to medical and nutritional needs, many people with PSP can live 10 or more years after the first symptoms of the disease. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Supranuclear Palsy, Progressive, 1, also known as progressive supranuclear palsy, is related to frontotemporal lobar degeneration with tdp43 inclusions, grn-related and semantic dementia, and has symptoms including seizures, tremor and photophobia. An important gene associated with Supranuclear Palsy, Progressive, 1 is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Neuroscience. The drugs Rivastigmine and Rasagiline have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related phenotypes are dysphagia and falls

Disease Ontology : 12 A movement disease characterized by serious and progressive problems with control of gait and balance, along with complex eye movement and thinking problems. It involves gradual deterioration and death of specific volumes of the brain.

Genetics Home Reference : 26 Progressive supranuclear palsy is a brain disorder that affects movement, vision, speech, and thinking ability (cognition). The signs and symptoms of this disorder usually become apparent in mid- to late adulthood, most often in a person's 60s. Most people with progressive supranuclear palsy survive 5 to 9 years after the disease first appears, although a few affected individuals have lived for more than a decade.

NIH Rare Diseases : 54 Progressive supranuclear palsy (PSP) is a degenerative neurologic disease due to damage to nerve cells in the brain. Signs and symptoms vary but may include loss of balance; blurring of vision; problems controlling eye movement; changes in mood, behavior and judgment; cognitive decline; and slowing and slurred speech. PSP is often misdiagnosed as Parkinson disease due to similar symptoms. Onset is usually after age 60 but may occur earlier. Most cases of PSP appear to be sporadic, but familial cases have been reported. Some cases have been found to be caused by a mutation in the MAPT gene, and other genetic factors are being studied. There is currently no effective treatment for PSP, and symptoms usually do not respond to medications. Research regarding potential treatments is ongoing.

OMIM : 58 Progressive supranuclear palsy (PSP) is the second most frequent cause of degenerative parkinsonism. In addition to parkinsonism, the clinical symptoms include early postural instability, supranuclear gaze palsy, and cognitive decline. Neuropathologically, the disorder is characterized by abundant neurofibrillary tangles, which differ in both distribution and composition from those associated with Alzheimer disease. In progressive supranuclear palsy, the tangles are primarily localized to subcortical regions and are found in both neurons and glia, whereas in Alzheimer disease they are more widespread, largely cortical, and limited to neurons. They also have different characteristics at the ultrastructural level (Baker et al., 1999). Kertesz (2003) suggested the term 'Pick complex' to represent the overlapping syndromes of frontotemporal dementia (FTD; 600274), primary progressive aphasia (PPA), corticobasal degeneration (CBD), progressive supranuclear palsy, and FTD with motor neuron disease. He noted that frontotemporal dementia may also be referred to as 'clinical Pick disease,' and that the term 'Pick disease' (172700) should be restricted to the pathologic finding of Pick bodies. (601104)

NINDS : 55 Progressive supranuclear palsy (PSP) is a rare brain disorder that causes serious and progressive problems with control of gait and balance, along with complex eye movement and thinking problems. One of the classic signs of the disease is an inability to aim the eyes properly, which occurs because of lesions in the area of the brain that coordinates eye movements. Some individuals describe this effect as a blurring. Affected individuals often show alterations of mood and behavior, including depression and apathy as well as progressive mild dementia. The disorder's long name indicates that the disease begins slowly and continues to get worse (progressive), and causes weakness (palsy) by damaging certain parts of the brain above pea-sized structures called nuclei that control eye movements (supranuclear). PSP was first described as a distinct disorder in 1964, when three scientists published a paper that distinguished the condition from Parkinson's disease. It is sometimes referred to as Steele-Richardson-Olszewski syndrome, reflecting the combined names of the scientists who defined the disorder. Although PSP gets progressively worse, no one dies from PSP itself.

UniProtKB/Swiss-Prot : 76 Progressive supranuclear palsy 1: Characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.

Wikipedia : 77 Progressive supranuclear palsy (PSP), also known as Steele–Richardson–Olszewski syndrome, is a... more...

Related Diseases for Supranuclear Palsy, Progressive, 1

Diseases in the Supranuclear Palsy, Progressive, 1 family:

Supranuclear Palsy, Progressive, 2 Supranuclear Palsy, Progressive, 3

Diseases related to Supranuclear Palsy, Progressive, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)
# Related Disease Score Top Affiliating Genes
1 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 32.8 GRN MAPT RPS27A
2 semantic dementia 32.7 APOE GRN MAPT RPS27A
3 corticobasal degeneration 32.6 LRRK2 MAPT RPS27A
4 pick disease of brain 32.4 APOE APP CHAT GRN MAPT RPS27A
5 frontotemporal dementia 32.2 ACHE APOE APP GRN LRRK2 MAPT
6 perry syndrome 31.9 GRN SLC6A3 SNCA TH
7 striatonigral degeneration 31.2 DRD2 SLC6A3 SNCA
8 tremor 31.0 LRRK2 MAPT PRKN SNCA
9 postencephalitic parkinson disease 31.0 LRRK2 MAPT SNCA
10 aphasia 31.0 APOE APP GRN MAPT SNCA
11 dystonia 30.8 DRD2 PRKN SLC6A3 TH
12 progressive non-fluent aphasia 30.7 GRN MAPT
13 cerebral amyloid angiopathy, cst3-related 30.6 APOE APP MAPT
14 essential tremor 30.6 LRRK2 PRKN SLC6A3 SNCA
15 akinetic mutism 30.5 MAPT SLC6A3
16 rem sleep behavior disorder 30.5 ACHE LRRK2 RPS27A SLC6A3 SNCA
17 brain injury 30.5 APOE DRD2 MAPT
18 ideomotor apraxia 30.5 GRN MAPT
19 mutism 30.4 GRN SLC6A3
20 agraphia 30.3 ACHE GRN MAPT
21 major depressive disorder 30.3 APOE CRHR1 DRD2 SLC6A3
22 motor neuron disease 30.0 CHAT GRN MAPT RPS27A SNCA
23 movement disease 29.9 DRD2 LRRK2 MAPT PARK7 PRKN SLC6A3
24 amyotrophic lateral sclerosis 1 29.9 APP CHAT GRN MAPT NEFL RPS27A
25 multiple system atrophy 1 29.8 DRD2 LRRK2 MAPT PRKN RPS27A SLC6A3
26 alzheimer disease 29.6 ACHE APOE APP CHAT GRN MAPT
27 parkinson disease, late-onset 29.6 ACHE APOE APP CHAT DRD2 LRRK2
28 synucleinopathy 29.6 APP LRRK2 MAPT PARK7 PRKN SLC6A3
29 dementia 29.2 ACHE APOE APP CHAT GRN LRRK2
30 supranuclear palsy, progressive, 2 12.5
31 supranuclear palsy, progressive, 3 12.5
32 pneumothorax, primary spontaneous 11.9
33 parkinson-dementia syndrome 11.7
34 dysphagia 11.6
35 swallowing disorders 11.2
36 progressive supranuclear palsy-progressive non-fluent aphasia syndrome 11.2
37 progressive supranuclear palsy-corticobasal syndrome 11.2
38 progressive supranuclear palsy-pure akinesia with gait freezing syndrome 11.2
39 classic progressive supranuclear palsy syndrome 11.0
40 depression 10.5
41 simultanagnosia 10.5 APOE MAPT
42 posterior cortical atrophy 10.5 APOE MAPT
43 episodic kinesigenic dyskinesia 1 10.4
44 schizophrenia 10.4
45 torticollis 10.4
46 apraxia 10.4
47 adenocarcinoma 10.4
48 hereditary late-onset parkinson disease 10.4 LRRK2 SNCA
49 lateral sclerosis 10.4
50 neuronal intranuclear inclusion disease 10.4 MAPT RPS27A SNCA

Graphical network of the top 20 diseases related to Supranuclear Palsy, Progressive, 1:



Diseases related to Supranuclear Palsy, Progressive, 1

Symptoms & Phenotypes for Supranuclear Palsy, Progressive, 1

Human phenotypes related to Supranuclear Palsy, Progressive, 1:

60 33 (show all 45)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 60 33 hallmark (90%) Very frequent (99-80%) HP:0002015
2 falls 60 33 hallmark (90%) Very frequent (99-80%) HP:0002527
3 impulsivity 60 33 hallmark (90%) Very frequent (99-80%) HP:0100710
4 postural instability 60 33 hallmark (90%) Very frequent (99-80%) HP:0002172
5 unsteady gait 60 33 hallmark (90%) Very frequent (99-80%) HP:0002317
6 supranuclear ophthalmoplegia 60 33 hallmark (90%) Very frequent (99-80%) HP:0000623
7 neuronal loss in central nervous system 60 33 hallmark (90%) Very frequent (99-80%) HP:0002529
8 abnormal synaptic transmission 60 33 hallmark (90%) Very frequent (99-80%) HP:0012535
9 depressivity 60 33 frequent (33%) Frequent (79-30%) HP:0000716
10 delayed speech and language development 60 33 frequent (33%) Frequent (79-30%) HP:0000750
11 cerebral cortical atrophy 60 33 frequent (33%) Frequent (79-30%) HP:0002120
12 memory impairment 60 33 frequent (33%) Frequent (79-30%) HP:0002354
13 aphasia 60 33 frequent (33%) Frequent (79-30%) HP:0002381
14 blepharospasm 60 33 frequent (33%) Frequent (79-30%) HP:0000643
15 bradykinesia 60 33 frequent (33%) Frequent (79-30%) HP:0002067
16 slow saccadic eye movements 60 33 frequent (33%) Frequent (79-30%) HP:0000514
17 vertical supranuclear gaze palsy 60 33 frequent (33%) Frequent (79-30%) HP:0000511
18 gliosis 60 33 frequent (33%) Frequent (79-30%) HP:0002171
19 pseudobulbar signs 60 33 frequent (33%) Frequent (79-30%) HP:0002200
20 tremor 60 33 very rare (1%) Occasional (29-5%) HP:0001337
21 rigidity 60 33 occasional (7.5%) Occasional (29-5%) HP:0002063
22 dementia 60 33 occasional (7.5%) Occasional (29-5%) HP:0000726
23 limb dystonia 33 very rare (1%) HP:0002451
24 frontal release signs 33 very rare (1%) HP:0000743
25 supranuclear gaze palsy 60 33 Very frequent (99-80%) HP:0000605
26 abnormality of eye movement 60 Occasional (29-5%)
27 diplopia 33 HP:0000651
28 dysarthria 33 HP:0001260
29 cognitive impairment 60 Frequent (79-30%)
30 photophobia 33 HP:0000613
31 irritability 33 HP:0000737
32 gait imbalance 33 HP:0002141
33 dystonia 60 Frequent (79-30%)
34 blurred vision 33 HP:0000622
35 parkinsonism 33 HP:0001300
36 neurofibrillary tangles 33 HP:0002185
37 apathy 33 HP:0000741
38 eyelid apraxia 33 HP:0000658
39 akinesia 33 HP:0002304
40 mutism 33 HP:0002300
41 neuronal loss in basal ganglia 33 HP:0200147
42 axial dystonia 33 HP:0002530
43 retrocollis 33 HP:0002544
44 frontolimbic dementia 33 HP:0002439
45 granulovacuolar degeneration 33 HP:0002528

Symptoms via clinical synopsis from OMIM:

58
Head And Neck Eyes:
diplopia
photophobia
blurred vision
eyelid apraxia
supranuclear gaze palsy

Abdomen Gastrointestinal:
dysphagia

Neurologic Central Nervous System:
dysarthria
gait imbalance
falls
rigidity
bradykinesia
more
Neurologic Behavioral Psychiatric Manifestations:
irritability
apathy
forgetfulness
frontal release signs (45%)

Clinical features from OMIM:

601104

UMLS symptoms related to Supranuclear Palsy, Progressive, 1:


seizures, tremor, photophobia, back pain, ophthalmoplegia, pain, headache, bradykinesia, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, forgetful, muscle rigidity, poor mobility

MGI Mouse Phenotypes related to Supranuclear Palsy, Progressive, 1:

47 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.5 ACHE APOE APP CBSL CHAT CRHR1
2 homeostasis/metabolism MP:0005376 10.41 ACHE APOE APP CBSL CHAT CRHR1
3 growth/size/body region MP:0005378 10.38 ACHE APOE APP CBSL CHAT DRD2
4 cellular MP:0005384 10.36 APOE APP CBSL DRD2 GRN LRRK2
5 cardiovascular system MP:0005385 10.34 APOE APP CBSL CHAT CRHR1 DRD2
6 mortality/aging MP:0010768 10.33 ACHE APOE APP CBSL CHAT CRHR1
7 nervous system MP:0003631 10.33 ACHE APOE APP CBSL CHAT CRHR1
8 hematopoietic system MP:0005397 10.22 ACHE APOE APP CBSL DRD2 GRN
9 integument MP:0010771 10.22 APOE APP CBSL DRD2 LRRK2 MAPT
10 immune system MP:0005387 10.19 APOE APP CBSL DRD2 GRN LRRK2
11 muscle MP:0005369 10.13 ACHE APOE APP CBSL CHAT DRD2
12 no phenotypic analysis MP:0003012 10.11 ACHE APOE APP CRHR1 DRD2 GRN
13 normal MP:0002873 10.1 APP CHAT CRHR1 DRD2 LRRK2 MAPT
14 reproductive system MP:0005389 9.91 ACHE APOE APP CBSL CHAT DRD2
15 respiratory system MP:0005388 9.85 ACHE APOE CBSL CHAT CRHR1 DRD2
16 taste/olfaction MP:0005394 9.35 APOE DRD2 MAPT SLC6A3 SNCA
17 vision/eye MP:0005391 9.28 ACHE APOE CBSL CHAT CRHR1 GRN

Drugs & Therapeutics for Supranuclear Palsy, Progressive, 1

Drugs for Supranuclear Palsy, Progressive, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivastigmine Approved, Investigational Phase 3,Phase 2 123441-03-2 77991
2
Rasagiline Approved Phase 3 136236-51-6 3052776
3
Riluzole Approved, Investigational Phase 3 1744-22-5 5070
4
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
5
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
6
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 303-98-0 5281915
7 Neuroprotective Agents Phase 3,Phase 2
8 Protective Agents Phase 3,Phase 2,Phase 1
9 Cholinesterase Inhibitors Phase 3,Phase 2
10 Cholinergic Agents Phase 3,Phase 2
11 Neurotransmitter Agents Phase 3,Phase 2
12 Monoamine Oxidase Inhibitors Phase 3
13 Trace Elements Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
14 Vitamins Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
15 Nutrients Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
16 Ubiquinone Phase 2, Phase 3,Phase 3
17 Micronutrients Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
18 Anticonvulsants Phase 3,Phase 2
19 Excitatory Amino Acids Phase 3
20 Excitatory Amino Acid Antagonists Phase 3
21 Anti-Bacterial Agents Phase 3
22 Anti-Infective Agents Phase 3
23 Psychotropic Drugs Phase 3,Phase 2,Phase 1
24 Antiparkinson Agents Phase 3,Phase 2
25 Serotonin Agents Phase 3
26 Serotonin Antagonists Phase 3
27 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
28 Antipsychotic Agents Phase 3
29 Serotonin 5-HT2 Receptor Antagonists Phase 3
30 Tranquilizing Agents Phase 3,Phase 2,Phase 1
31
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
32
Donepezil Approved Phase 2 120014-06-4 3152
33
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
34
Acetylcarnitine Approved, Investigational Phase 1, Phase 2 3040-38-8 7045767
35
Lithium carbonate Approved Phase 1, Phase 2 554-13-2
36
Droxidopa Approved, Investigational Phase 2 23651-95-8 443940
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2,Not Applicable 59-30-3 6037
38 Pharmaceutical Solutions Phase 1, Phase 2,Phase 2
39 Anesthetics Phase 1, Phase 2
40 Nootropic Agents Phase 2,Phase 1
41 GABA Agents Phase 2
42 Antimanic Agents Phase 2,Phase 1
43 Alpha-lipoic Acid Phase 1, Phase 2
44 Antioxidants Phase 1, Phase 2
45 Vitamin B Complex Phase 1, Phase 2,Not Applicable
46 Folate Phase 1, Phase 2,Not Applicable
47 Vitamin B9 Phase 1, Phase 2,Not Applicable
48 carnitine Phase 1, Phase 2
49 Thioctic Acid Phase 1, Phase 2
50 Antidepressive Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy Terminated NCT01187888 Phase 3 Rasagiline;Sugar pill
2 Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Completed NCT01110720 Phase 2, Phase 3 Davunetide;Placebo
3 Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy Recruiting NCT02839642 Phase 3 Rivastigmine;Placebo
4 Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) Completed NCT00382824 Phase 2, Phase 3 CoenzymeQ10
5 Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) Terminated NCT00211224 Phase 3 Riluzole
6 Effects of Coenzyme Q10 in PSP and CBD Completed NCT00532571 Phase 2, Phase 3 CoQ10
7 Study About Efficacy and Safety to Treat Multi-System-Atrophy Completed NCT00146809 Phase 3 Minocyline
8 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
9 Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism Unknown status NCT01824121 Phase 1, Phase 2
10 Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Unknown status NCT00139373 Phase 2 donepezil
11 Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy Unknown status NCT00522015 Phase 2 rivastigmine
12 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Recruiting NCT03391765 Phase 2 ABBV-8E12
13 A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). Active, not recruiting NCT02985879 Phase 2 placebo;ABBV-8E12
14 Study of BIIB092 in Participants With Progressive Supranuclear Palsy Active, not recruiting NCT03068468 Phase 2 BIIB092;Placebo
15 Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Completed NCT00385710 Phase 2 valproic acid;Placebo
16 Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Completed NCT01537549 Phase 1, Phase 2 alpha-lipoic acid and L-acetyl carnitine
17 A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Completed NCT00703677 Phase 1, Phase 2 Lithium
18 Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy Completed NCT00328874 Phase 2 Coenzyme Q10
19 Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy Completed NCT00005903 Phase 2 GDNF & Synchro Med Infusion System
20 Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Completed NCT01056965 Phase 2 davunetide (AL-108, NAP);Placebo nasal spray
21 Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Not yet recruiting NCT03446807 Phase 2 Droxidopa;Placebo Oral Tablet
22 The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography Completed NCT01824056 Phase 2 18F-FDG
23 Novel Neuroimage Study in Tauopathies With Parkinsonism Active, not recruiting NCT03386669 Phase 2 F-18
24 Young Plasma Transfusions for Progressive Supranuclear Palsy Active, not recruiting NCT02460731 Phase 1
25 Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Completed NCT02494024 Phase 1 Single dose C2N-8E12;Single dose placebo
26 Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Active, not recruiting NCT03413319 Phase 1 ABBV-8E12
27 Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Completed NCT02460094 Phase 1 BIIB092;Placebo
28 Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Completed NCT02167594 Phase 1 18F-AV-1451;florbetapir F18
29 A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Active, not recruiting NCT02422485 Phase 1 Salsalate
30 Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 Active, not recruiting NCT02658916 Phase 1 BIIB092
31 Safety Study of TPI-287 to Treat CBS and PSP Active, not recruiting NCT02133846 Phase 1 TPI 287 2 mg/m2;TPI-287 20 mg/m2;Placebo;TPI-287 6.3 mg/m2
32 Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Completed NCT02103894 Phase 1 [18F]T807 ([18F]MNI-777)
33 Phase 1 Test-retest Evaluation of [18F]MNI-958 PET Recruiting NCT03545789 Phase 1 [18F]MNI-958
34 Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood Completed NCT02104401 Phase 1
35 Postural Instability in Progressive Supranuclear Palsy Unknown status NCT01563276
36 Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease and Progressive Supranuclear Palsy. Unknown status NCT01815281 Not Applicable
37 Diagnostic and Prognostic Biomarkers in Parkinson Disease Unknown status NCT00653783
38 Parkinson's Disease, Diagnostic Observations (PADDO) Unknown status NCT01249768
39 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 l-123 Ioflupane
40 Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized Unknown status NCT01403519
41 PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease Unknown status NCT02801110
42 Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy Not yet recruiting NCT03638505
43 Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy Completed NCT01049399 Not Applicable tideglusib;tideglusib;placebo
44 Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy Completed NCT02734485 Not Applicable
45 A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy Recruiting NCT02605785 Not Applicable F-18 AV 1451
46 Rehabilitation in Patients With Progressive Supranuclear Palsy Completed NCT02109393 Not Applicable
47 Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls Completed NCT01348061
48 PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK Recruiting NCT02778607
49 A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. Completed NCT00605930 Not Applicable
50 Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration Completed NCT01174771

Search NIH Clinical Center for Supranuclear Palsy, Progressive, 1

Cochrane evidence based reviews: supranuclear palsy, progressive

Genetic Tests for Supranuclear Palsy, Progressive, 1

Genetic tests related to Supranuclear Palsy, Progressive, 1:

# Genetic test Affiliating Genes
1 Progressive Supranuclear Ophthalmoplegia 30

Anatomical Context for Supranuclear Palsy, Progressive, 1

MalaCards organs/tissues related to Supranuclear Palsy, Progressive, 1:

42
Brain, Eye, Testes, Cortex, Cerebellum, Thalamus, Tongue

Publications for Supranuclear Palsy, Progressive, 1

Articles related to Supranuclear Palsy, Progressive, 1:

(show top 50) (show all 1569)
# Title Authors Year
1
Electrophysiological and clinical assessment of dysautonomia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP): a comparative study. ( 30620042 )
2019
2
Progressive Supranuclear Palsy-like Syndrome from Possible Cerebral Amyloid Angiopathy. ( 30457071 )
2019
3
MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy. ( 30373485 )
2019
4
MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. ( 30468693 )
2019
5
Imaging in the diagnosis of progressive supranuclear palsy. ( 30542948 )
2019
6
Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status. ( 30712468 )
2019
7
Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. ( 30726566 )
2019
8
Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. ( 30796010 )
2019
9
Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy - A double-validation whole-brain meta-analysis. ( 30831462 )
2019
10
Improved language production with transcranial direct current stimulation in progressive supranuclear palsy. ( 30836131 )
2019
11
Accumulation of Tau Protein, Metabolism and Perfusion-Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS). ( 30837933 )
2019
12
A Home-Based, Music-Cued Movement Program Is Feasible and May Improve Gait in Progressive Supranuclear Palsy. ( 30837939 )
2019
13
Virtual reality-based cognitive rehabilitation in progressive supranuclear palsy. ( 30854776 )
2019
14
Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. ( 30882841 )
2019
15
The language profile of progressive supranuclear palsy. ( 30884283 )
2019
16
How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. ( 30884545 )
2019
17
In vivo binding of a tau imaging probe, [11 C]PBB3, in patients with progressive supranuclear palsy. ( 30892739 )
2019
18
Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation. ( 30894142 )
2019
19
Was the subject portrayed in "A Man" by Cornelis Anthonisz around 1530 really affected by progressive supranuclear palsy? ( 30324250 )
2019
20
Atypical parkinsonism of progressive supranuclear palsy-parkinsonism (PSP-P) phenotype with rare variants in FBXO7 and VPS35 genes associated with Lewy body pathology. ( 30374525 )
2019
21
Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans. ( 29973911 )
2018
22
Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging? ( 29973914 )
2018
23
Neurogenic bladder in progressive supranuclear palsy: A comparison with Parkinson's disease and multiple system atrophy. ( 29356135 )
2018
24
Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. ( 29254097 )
2018
25
Anti-inflammatory drug use and progressive supranuclear palsy. ( 29307562 )
2018
26
DCTN1 F52L mutation case of Perry syndrome with progressive supranuclear palsy-like tauopathy. ( 29499916 )
2018
27
Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. ( 29926172 )
2018
28
Specificity and sensitivity of magnetic resonance imaging findings in the diagnosis of progressive supranuclear palsy. ( 28432758 )
2018
29
Association between semantic dementia and progressive supranuclear palsy. ( 29661923 )
2018
30
[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. ( 29703774 )
2018
31
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease. ( 29281045 )
2018
32
Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No. ( 30363409 )
2018
33
Stereotypic behaviours in frontotemporal dementia and progressive supranuclear palsy. ( 30399478 )
2018
34
The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage. ( 29728749 )
2018
35
Levodopa-induced dystonia in a patient with possible progressive supranuclear palsy with progressive gait freezing. ( 29627008 )
2018
36
Progressive supranuclear palsy responding to intravenous thiamine: superimposed Wernicke's encephalopathy? ( 30131406 )
2018
37
Chronic meningoencephalitis with mixed pathology mimics progressive supranuclear palsy. ( 30567127 )
2018
38
Prominent tongue and jaw tremor in a patient with probable Progressive Supranuclear Palsy. ( 30271811 )
2018
39
Simple linear brainstem MRI measurements in the differential diagnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy. ( 29196955 )
2018
40
A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. ( 29710120 )
2018
41
Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. ( 29746401 )
2018
42
Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. ( 30178175 )
2018
43
Evaluation of Retinal Changes in Progressive Supranuclear Palsy and Parkinson Disease. ( 29240574 )
2018
44
Track density imaging in progressive supranuclear palsy: A pilot study. ( 30474903 )
2018
45
Medical decision-making in progressive supranuclear palsy: A comparison to other neurodegenerative disorders. ( 30514650 )
2018
46
Florid Nonmotor Manifestations of a Pathologically proven Progressive Supranuclear Palsy. ( 30532377 )
2018
47
In vivo evidence for decreased scyllo-inositol levels in the supplementary motor area of patients with Progressive Supranuclear Palsy: A proton MR spectroscopy study. ( 30558837 )
2018
48
Visual Search in Progressive Supranuclear Palsy. ( 30570703 )
2018
49
Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. ( 30598430 )
2018
50
Is the Latency from Progressive Supranuclear Palsy Onset to Diagnosis Improving? ( 30637280 )
2018

Variations for Supranuclear Palsy, Progressive, 1

UniProtKB/Swiss-Prot genetic disease variations for Supranuclear Palsy, Progressive, 1:

76
# Symbol AA change Variation ID SNP ID
1 MAPT p.Arg5Leu VAR_019661 rs63750959
2 MAPT p.Gly620Val VAR_037439 rs63751391

ClinVar genetic disease variations for Supranuclear Palsy, Progressive, 1:

6 (show all 12)
# Gene Variation Type Significance SNP ID Assembly Location
1 MAPT NM_005910.5(MAPT): c.902C> T (p.Pro301Leu) single nucleotide variant Pathogenic rs63751273 GRCh37 Chromosome 17, 44087755: 44087755
2 MAPT NM_005910.5(MAPT): c.902C> T (p.Pro301Leu) single nucleotide variant Pathogenic rs63751273 GRCh38 Chromosome 17, 46010389: 46010389
3 MAPT NM_016835.4(MAPT): c.14G> T (p.Arg5Leu) single nucleotide variant Pathogenic rs63750959 GRCh37 Chromosome 17, 44039717: 44039717
4 MAPT NM_016835.4(MAPT): c.14G> T (p.Arg5Leu) single nucleotide variant Pathogenic rs63750959 GRCh38 Chromosome 17, 45962351: 45962351
5 MAPT NM_016835.4(MAPT): c.2006C> T (p.Ser669Leu) single nucleotide variant Pathogenic rs63750425 GRCh37 Chromosome 17, 44096041: 44096041
6 MAPT NM_016835.4(MAPT): c.2006C> T (p.Ser669Leu) single nucleotide variant Pathogenic rs63750425 GRCh38 Chromosome 17, 46018675: 46018675
7 MAPT NM_016835.4(MAPT): c.1859G> T (p.Gly620Val) single nucleotide variant Pathogenic rs63751391 GRCh37 Chromosome 17, 44087761: 44087761
8 MAPT NM_016835.4(MAPT): c.1859G> T (p.Gly620Val) single nucleotide variant Pathogenic rs63751391 GRCh38 Chromosome 17, 46010395: 46010395
9 MAPT NM_001123066.3(MAPT): c.623delG (p.Gly208Alafs) deletion Uncertain significance rs773149360 GRCh38 Chromosome 17, 45983427: 45983427
10 MAPT NM_001123066.3(MAPT): c.623delG (p.Gly208Alafs) deletion Uncertain significance rs773149360 GRCh37 Chromosome 17, 44060793: 44060793
11 MAPT NM_016841.4(MAPT): c.47G> T (p.Gly16Val) single nucleotide variant Uncertain significance rs755131800 GRCh37 Chromosome 17, 44039750: 44039750
12 MAPT NM_016841.4(MAPT): c.47G> T (p.Gly16Val) single nucleotide variant Uncertain significance rs755131800 GRCh38 Chromosome 17, 45962384: 45962384

Expression for Supranuclear Palsy, Progressive, 1

Search GEO for disease gene expression data for Supranuclear Palsy, Progressive, 1.

Pathways for Supranuclear Palsy, Progressive, 1

Pathways related to Supranuclear Palsy, Progressive, 1 according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 APOE APP DRD2 LRRK2 MAPT NDUFS4
2 11.86 APOE APP LRRK2 MAPT NEFL PARK7
3
Show member pathways
11.75 DRD2 SLC6A3 TH
4 11.55 CHAT NEFL TH
5 11.36 LRRK2 PARK7 PRKN SLC6A3 SNCA TH
6 11.26 APOE APP MAPT
7
Show member pathways
11.21 ACHE SLC6A3 TH
8 11.06 PARK7 PRKN SLC6A3 SNCA TH
9
Show member pathways
10.89 ACHE CHAT TH
10 10.58 ACHE CHAT TH
11 10.57 PRKN RPS27A
12 10.3 ACHE CHAT

GO Terms for Supranuclear Palsy, Progressive, 1

Cellular components related to Supranuclear Palsy, Progressive, 1 according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.88 APOE DRD2 LRRK2 MAPT TH
2 neuronal cell body GO:0043025 9.73 APOE LRRK2 MAPT SLC6A3 SNCA TH
3 membrane raft GO:0045121 9.72 APP LRRK2 MAPT PARK7 SLC6A3
4 neuromuscular junction GO:0031594 9.69 ACHE APP NEFL
5 synaptic vesicle membrane GO:0030672 9.67 DRD2 LRRK2 SNCA
6 presynapse GO:0098793 9.67 CHAT PARK7 PRKN SNCA
7 mitochondrial respiratory chain complex I GO:0005747 9.61 NDUFS4 PARK7 SNCA
8 neuron projection GO:0043005 9.61 APP CHAT LRRK2 MAPT NEFL PARK7
9 terminal bouton GO:0043195 9.58 LRRK2 SNCA TH
10 growth cone GO:0030426 9.55 APP LRRK2 MAPT NEFL SNCA
11 synaptic cleft GO:0043083 9.54 ACHE APOE
12 dopaminergic synapse GO:0098691 9.52 DRD2 SLC6A3
13 main axon GO:0044304 9.46 APP MAPT
14 axon GO:0030424 9.28 APP DRD2 LRRK2 MAPT NEFL PARK7
15 mitochondrion GO:0005739 10.09 LRRK2 MAPT NDUFS4 PARK7 PRKN SNCA

Biological processes related to Supranuclear Palsy, Progressive, 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.95 APOE APP MAPT PARK7 PRKN
2 cellular protein metabolic process GO:0044267 9.92 APOE APP PRKN RPS27A SNCA
3 autophagy GO:0006914 9.91 DRD2 LRRK2 PARK7 PRKN
4 response to ethanol GO:0045471 9.9 DRD2 SLC6A3 TH
5 mitochondrion organization GO:0007005 9.88 LRRK2 PARK7 PRKN
6 cellular response to oxidative stress GO:0034599 9.88 LRRK2 PARK7 SNCA
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.87 APP PARK7 SNCA
8 response to oxidative stress GO:0006979 9.87 APOE APP LRRK2 PRKN
9 negative regulation of neuron apoptotic process GO:0043524 9.85 APOE NEFL PARK7 PRKN SNCA
10 excitatory postsynaptic potential GO:0060079 9.83 DRD2 LRRK2 SNCA
11 negative regulation of cell death GO:0060548 9.83 DRD2 PARK7 PRKN
12 positive regulation of protein binding GO:0032092 9.83 APP LRRK2 PRKN
13 regulation of autophagy GO:0010506 9.82 LRRK2 MAPT PRKN
14 learning GO:0007612 9.81 APP PRKN TH
15 locomotory behavior GO:0007626 9.8 APP DRD2 PRKN SLC6A3 TH
16 synapse organization GO:0050808 9.78 APP MAPT SNCA
17 adult locomotory behavior GO:0008344 9.78 APP PARK7 PRKN SNCA
18 response to cocaine GO:0042220 9.76 DRD2 SLC6A3 SNCA
19 response to nicotine GO:0035094 9.75 DRD2 SLC6A3 TH
20 positive regulation of long-term synaptic potentiation GO:1900273 9.72 APP DRD2
21 response to iron ion GO:0010039 9.72 DRD2 SLC6A3
22 startle response GO:0001964 9.72 DRD2 PRKN
23 axon development GO:0061564 9.72 MAPT NEFL
24 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.72 LRRK2 PARK7
25 negative regulation of protein phosphorylation GO:0001933 9.72 DRD2 LRRK2 PARK7 PRKN SNCA
26 striatum development GO:0021756 9.71 DRD2 LRRK2
27 prepulse inhibition GO:0060134 9.71 DRD2 SLC6A3
28 cellular response to dopamine GO:1903351 9.71 LRRK2 PRKN
29 locomotory exploration behavior GO:0035641 9.71 APOE LRRK2
30 regulation of long-term neuronal synaptic plasticity GO:0048169 9.71 APP DRD2 SNCA
31 supramolecular fiber organization GO:0097435 9.7 MAPT SNCA
32 amyloid precursor protein metabolic process GO:0042982 9.7 ACHE APOE
33 virion assembly GO:0019068 9.69 APOE RPS27A
34 astrocyte activation GO:0048143 9.69 APP MAPT
35 negative regulation of long-term synaptic potentiation GO:1900272 9.69 APOE APP
36 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.69 LRRK2 PARK7 PRKN
37 regulation of dopamine metabolic process GO:0042053 9.68 PRKN SLC6A3
38 adenohypophysis development GO:0021984 9.68 DRD2 SLC6A3
39 amyloid fibril formation GO:1990000 9.68 APP MAPT
40 axonal transport of mitochondrion GO:0019896 9.68 MAPT NEFL
41 intracellular distribution of mitochondria GO:0048312 9.67 LRRK2 MAPT
42 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 CRHR1 DRD2
43 positive regulation of microglial cell activation GO:1903980 9.67 APP LRRK2
44 dopamine metabolic process GO:0042417 9.67 DRD2 PRKN SNCA
45 regulation of locomotion GO:0040012 9.66 LRRK2 SNCA
46 negative regulation of neuron death GO:1901215 9.65 APOE LRRK2 PARK7 PRKN SNCA
47 mating behavior GO:0007617 9.64 APP TH
48 regulation of mitochondrial fission GO:0090140 9.64 LRRK2 MAPT
49 negative regulation of oxidative stress-induced cell death GO:1903202 9.63 PARK7 PRKN
50 positive regulation of autophagy of mitochondrion GO:1903599 9.62 PARK7 PRKN

Molecular functions related to Supranuclear Palsy, Progressive, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.91 ACHE APOE DRD2 LRRK2 MAPT PARK7
2 enzyme binding GO:0019899 9.73 APP MAPT PARK7 PRKN SNCA TH
3 tubulin binding GO:0015631 9.58 LRRK2 MAPT PRKN
4 ubiquitin-specific protease binding GO:1990381 9.46 PARK7 PRKN
5 cuprous ion binding GO:1903136 9.37 PARK7 SNCA
6 phospholipase binding GO:0043274 9.33 NEFL PRKN SNCA
7 lipoprotein particle binding GO:0071813 9.32 APOE MAPT
8 identical protein binding GO:0042802 9.28 APOE APP DRD2 LRRK2 MAPT NEFL
9 dopamine binding GO:0035240 9.13 DRD2 SLC6A3 TH

Sources for Supranuclear Palsy, Progressive, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....